Compare · MCK vs SCNX
MCK vs SCNX
Side-by-side comparison of McKesson Corporation (MCK) and Scienture Holdings Inc. (SCNX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MCK and SCNX operate in Other Pharmaceuticals (Health Care), so they compete in similar markets.
- MCK is the larger of the two at $105.52B, about 6219.2x SCNX ($17.0M).
- MCK has been more active in the news (8 items in the past 4 weeks vs 4 for SCNX).
- MCK has more recent analyst coverage (25 ratings vs 0 for SCNX).
- Company
- McKesson Corporation
- Scienture Holdings Inc.
- Price
- -
- -
- Market cap
- $105.52B
- $17.0M
- 1M return
- -
- +16.23%
- 1Y return
- -
- -60.36%
- Industry
- Other Pharmaceuticals
- Other Pharmaceuticals
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 8
- 4
- Recent ratings
- 25
- 0
McKesson Corporation
McKesson Corporation provides healthcare supply chain management, retail pharmacy, community oncology and specialty care, and healthcare information solutions in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment offers CoverMyMeds solution to help patients get the medications; RelayHealth, a workflow solution; RxCrossroads solution for therapies and interventions to biopharma manufacturers; and McKesson Prescription Automation, a customized pharmacy automation technology; and Multi-Client Central Fill as a Service, a pharmacy. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.
Latest MCK
- McKesson Signs Agreement to Acquire Precision Medicine Group, LLC
- RBC Capital Mkts initiated coverage on McKesson with a new price target
- SEC Form 4 filed by EVP and Chief Strategy Officer Srinivasan Ramesh (Nmn)
- Director Lerman Bradley E sold $268,590 worth of shares (301 units at $892.33), closing all direct ownership in the company (SEC Form 4)
- New insider Srinivasan Ramesh (Nmn) claimed ownership of 11,959 shares (SEC Form 3)
- SEC Form 10-Q filed by McKesson Corporation
- McKesson Reports Fiscal 2027 First Quarter Results and Raises Full Year Adjusted EPS Guidance
- McKesson Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- McKesson Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- SEC Form 4 filed by Director Hinton James H.
Latest SCNX
- Scienture Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SCIENTURE Reports Q2 2026 Results with Approximately 510% Sequential Revenue Growth from Q1 2026 and Significant Improvement in Operating Performance
- SEC Form 10-Q filed by Scienture Holdings Inc.
- SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal Spray
- SCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to Wholesalers
- SCIENTURE Expands Arbli™ Payor Coverage and Commercial Access, Adding Approximately 12.5 Million Covered Lives Nationwide
- SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team
- SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC
- SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041
- Scienture Holdings Inc. filed SEC Form 8-K: Leadership Update